Akero Therapeutics Inc. (AKRO)’s Financial Results Comparing With Kadmon Holdings Inc. (NYSE:KDMN)

Both Akero Therapeutics Inc. (NASDAQ:AKRO) and Kadmon Holdings Inc. (NYSE:KDMN) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akero Therapeutics Inc. 24 0.00 8.81M -3.22 0.00
Kadmon Holdings Inc. 3 0.00 82.41M -0.31 0.00

Table 1 highlights Akero Therapeutics Inc. and Kadmon Holdings Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Akero Therapeutics Inc. and Kadmon Holdings Inc.

Net Margins Return on Equity Return on Assets
Akero Therapeutics Inc. 36,723,634.85% 0% 0%
Kadmon Holdings Inc. 3,233,539,982.74% -41.6% -18.2%

Liquidity

Akero Therapeutics Inc.’s Current Ratio and Quick Ratio are 29.4 and 29.4 respectively. The Current Ratio and Quick Ratio of its competitor Kadmon Holdings Inc. are 3.9 and 3.9 respectively. Akero Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Kadmon Holdings Inc.

Analyst Recommendations

Akero Therapeutics Inc. and Kadmon Holdings Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Akero Therapeutics Inc. 0 0 0 0.00
Kadmon Holdings Inc. 0 0 1 3.00

Meanwhile, Kadmon Holdings Inc.’s consensus target price is $8, while its potential upside is 197.40%.

Institutional & Insider Ownership

The shares of both Akero Therapeutics Inc. and Kadmon Holdings Inc. are owned by institutional investors at 48.5% and 75.9% respectively. Insiders owned roughly 17.8% of Akero Therapeutics Inc.’s shares. Insiders Competitively, owned 0.43% of Kadmon Holdings Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akero Therapeutics Inc. 5.86% 27.17% 0% 0% 0% 32.1%
Kadmon Holdings Inc. -0.76% 15.42% 12.93% 15.42% -21.79% 25.96%

For the past year Akero Therapeutics Inc.’s stock price has bigger growth than Kadmon Holdings Inc.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of WilsonÂ’s disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.